Skip to main content

Wall Street Analysts Are Bullish on Top Healthcare Picks

Tipranks - Tipranks - Mon Nov 17, 2025

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Scholar Rock Holding (SRRK – Research Report), Twist Bioscience (TWST – Research Report) and Sarepta Therapeutics (SRPT – Research Report) with bullish sentiments.

Meet Your ETF AI Analyst

Scholar Rock Holding (SRRK)

Barclays analyst Etzer Darout maintained a Buy rating on Scholar Rock Holding on November 14 and set a price target of $45.00. The company’s shares closed last Friday at $37.41.

According to TipRanks.com, Darout is a 5-star analyst with an average return of 24.0% and a 55.8% success rate. Darout covers the Healthcare sector, focusing on stocks such as Protagonist Therapeutics, Monopar Therapeutics Inc, and Arvinas Holding Company. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Scholar Rock Holding with a $47.33 average price target, which is a 35.3% upside from current levels. In a report issued on November 14, BMO Capital also maintained a Buy rating on the stock with a $50.00 price target.

See the top stocks recommended by analysts >>

Twist Bioscience (TWST)

In a report issued on November 14, Luke Sergott from Barclays maintained a Buy rating on Twist Bioscience, with a price target of $37.00. The company’s shares closed last Friday at $26.87.

According to TipRanks.com, Sergott ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -4.2% and a 40.4% success rate. Sergott covers the Healthcare sector, focusing on stocks such as West Pharmaceutical Services, Fortrea Holdings Inc., and Pacific Biosciences. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Twist Bioscience with a $40.40 average price target, representing a 53.5% upside. In a report issued on November 3, Stephens also initiated coverage with a Buy rating on the stock with a $41.00 price target.

Sarepta Therapeutics (SRPT)

Mizuho Securities analyst Uy Ear reiterated a Buy rating on Sarepta Therapeutics yesterday and set a price target of $26.00. The company’s shares closed last Friday at $18.81.

According to TipRanks.com, Ear is a 1-star analyst with an average return of -1.3% and a 37.8% success rate. Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, ACADIA Pharmaceuticals, and Cartesian Therapeutics. ;'>

Sarepta Therapeutics has an analyst consensus of Hold, with a price target consensus of $18.35.

Read More on SRRK:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).